SonoPath
Clinical Sonography & Telecytology
EDUCATIONAL TELECONSULTATION SERVICES™



SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Finnegan Koroski

SPECIES
Canine

BREED
Lab X

SEX
Neutered Male

AGE
2 Years

WEIGHT
59.3 Pounds

INTERPRETED BY
Eric Lindquist, DMV
DABVP, Cert. IVUSS

IMAGING PERFORMED BY
Shari Reffi, CVT

HOSPITAL NAME
Mount Olive VH

REFERRING VET
Dr. Jones

INVOICE
46501

DATE
4/7/23

PRESENTING CLINICAL SIGNS

Large cranial abdominal mass found incidentally during lameness exam. 10# wgt. loss in 60 days. Meds: Vetprofen

Abnormal PE/Chem/CBC/UA Results: Alt 184, Alt 1633, TBili 0.6, Plt 614

ULTRASONOGRAPHIC EXAMINATION OF THE ABDOMEN

Urinary System

The **urinary bladder**, trigone, and pelvic urethra presented normal thicknesses and normal tone. The ureters were not visible which is normal. No uroliths or sediment were visualized and anechoic urine was present. No evidence of inflammatory or neoplastic changes were noted. Ureteral papillae were normal. The pelvic urethra was imaged 2.0 cm beyond the cystourethral junction. The pelvic urethra was imaged 3.0 cm beyond the cystourethral junction.

The residual prostate measured 1.0 cm.

The **kidneys** revealed normal size and structure, corticomedullary definition and ratio for this age. The cortices presented largely uniform texture with normal echogenic relationship to liver and spleen. Medullary structure differed distinctly from the cortex. The capsules were acceptably uniform without significant irregularities. The right kidney measured 6.58 cm. The left kidney measured 7.18 cm with slight pyelectasia noted.

Adrenal Glands

Both **adrenal glands** were visualized and recognized as having normal shape, size, position and echogenicity for this breed. The phrenic vasculature, glandular echogenicity and detail were unremarkable. Capsule, cortex, and medullary definition were normal for this age patient. The right adrenal gland measured 2.0 cm x 0.50 cm. The left adrenal gland measured 2.92 cm x 0.49 cm at the cranial pole and 0.65 cm at the caudal pole.

Spleen

The **spleen** presented a smooth homogeneous parenchyma hyperechoic to liver and renal cortical parenchyma. The capsule was smooth without noticeable expansion or deviation from within the spleen or adjacent pathology. The splenic vasculature demonstrated normal volume without signs of congestion or thrombosis. No sonographic evidence of acute or chronic inflammatory, neoplastic, or infarctual changes were noted.

Liver

The liver revealed an extensive mixed echogenic cystic and moderately complex mass measuring 17 cm x 10 cm. The mass deviated regional tissues caudally and impinged upon the portal hilus. It appeared to be deriving from the left medial liver. However, this could not be completely ascertained, given the complexity of the mass. CT evaluation warranted to assess for potential surgical planning. The gallbladder was unremarkable.

Gastrointestinal

Examination of the **gastrointestinal tract** revealed a stomach and intestine free of stasis, of normal wall thickness, acceptable curvilinear mural detail, and peristaltic activity. Small and large intestine demonstrated normal luminal chyme and stool consistency respectively. No obstructive or overt infiltrative disease was noted. No associated abnormal lymphatic activity was noted.

SonoPath
Clinical Sonography & Telecytology
EDUCATIONAL TELECONSULTATION SERVICES™






SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Finnegan Koroski

SPECIES
Canine

BREED
Lab X

SEX
Neutered Male

AGE
2 Years

WEIGHT
59.3 Pounds

INTERPRETED BY
Eric Lindquist, DMV
DABVP, Cert. IVUSS

IMAGING PERFORMED BY
Shari Reffi, CVT

HOSPITAL NAME
Mount Olive VH

REFERRING VET
Dr. Jones

INVOICE
46501

DATE
4/7/23

Pancreas

The base and limbs of the **pancreas** were observed to be largely isoechoic to surrounding omental fat. Pancreatic duct and capsular contour were acceptably normal and parenchyma respected normal curvilinear patterns. No overt evidence of active inflammatory or neoplastic disease was noted.

ULTRASONOGRAPHIC FINDINGS

- Extensive liver mass (likely left medial) with impingement upon the portal hilus and gallbladder

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

CT evaluation for surgical planning +/- ultrasound guided FNA of the mass could be considered for further definition. The remainder of the abdomen appeared unremarkable. Prognosis is very guarded. Significant inflammation associated with the mass is suspected, given the ALT elevations.

SonoPath CT Services are offered at the SonoPath Imaging and Veterinary Education Center, 141 Main St (rt 206), Andover, New Jersey, a 20-minute drive west on route 80/206 North from the route 80/287 interchange/Parsippany, New Jersey. More information can be found at

https://sonopath.com/services/sonopath-ct-services



SonoPath
Clinical Sonography & Telecytology

EDUCATIONAL TELECONSULTATION SERVICES™






SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT

Finnegan Koroski

SPECIES

Canine

BREED

Lab X

SEX

Neutered Male

AGE

2 Years

WEIGHT

59.3 Pounds

INTERPRETED BY

Eric Lindquist, DMV

DABVP, Cert. IVUSS

IMAGING PERFORMED BY

Shari Reffi, CVT

HOSPITAL NAME

Mount Olive VH

REFERRING VET

Dr. Jones

INVOICE

46501

DATE

4/7/23



SonoPath
Clinical Sonography & Telecytology
EDUCATIONAL TELECONSULTATION SERVICES™



SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT

Finnegan Koroski

SPECIES

Canine

BREED

Lab X

SEX

Neutered Male

AGE

2 Years

WEIGHT

59.3 Pounds

INTERPRETED BY

Eric Lindquist, DMV

DABVP, Cert. IVUSS

IMAGING PERFORMED BY

Shari Reffi, CVT

HOSPITAL NAME

Mount Olive VH

REFERRING VET

Dr. Jones

INVOICE

46501

DATE

4/7/23

The information and recommendations provided are based on the images presented by the referring veterinarian/sonographer. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance please contact me.

Eric Lindquist, DMV, DABVP, Cert. IVUSS, CEO of SonoPath.com

info@SonoPath.com

Hepatic Masses, Biliary Adenoma, and Biliary Adenocarcinoma

http://www.sonopath.com/HepaticMasses

Description: Hepatocellular carcinoma typically manifests in the liver's left lateral lobes, yet may cross over to the right lobes should it derive from the hilus. These masses often present cavitating, necrotic cores that are difficult to distinguish from hepatic abscesses. Vascular channels may also be involved, and bile duct obstruction is often present. Older felines often present solitary or multiple fluid-filled cysts within the hepatic parenchyma. The latter are typically benign cystadenomas and should be differentiated from: cystic adenocarcinoma; hepatic lymphoma (usually diffusely hyperechoic +/- FIV/FeLV association); metastatic neoplasia (diffuse hyper- to hypoechoic nodules secondary to mammary adenocarcinoma, splenic hemangiosarcoma, or pancreatic or intestinal adenocarcinoma); benign nodular hyperplasia (accompanied by minimal to no symptoms); hepatic cirrhosis (regenerative nodules); or rare carcinoids, fibrosarcomas, leiomyosarcomas, and osteosarcomas.

Clinical Signs: Possible clinical signs and physical exam findings include cranial abdominal organomegaly, sudden collapse associated with mass rupture, vomiting, ascites, jaundice (severe cases), and hypoglycemia secondary to a paraneoplastic syndrome. Sepsis and fever associated with secondary abscessation of the mass may also occur. Cats usually present with anorexia and lethargy.

Diagnostics: Routine biochemical analysis primarily shows liver enzyme elevation (i.e., ALT for cellular necrosis; SAP for hepatic congestion; elevated bilirubin for stasis/obstruction; bile acids > 75-100uM/L for significant function impairment). Staging of the disease with 3-view thoracic radiographs is essential, as is conducting a CBC, serum biochemistry, urinalysis, as well as abdominal and possibly also thoracic ultrasounds in order to provide the owner with adequate and well-informed options. Surgical and oncological referral is recommended after a coagulation panel has been assessed and ultrasound-guided biopsies of both normal and pathological tissue have been performed such that the disease is adequately characterized. In cases where surgical resection is impossible, direct chemoembolization of the tumor blood supply could be considered;



SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Finnegan Koroski

SPECIES
Canine

BREED
Lab X

SEX
Neutered Male

AGE
2 Years

WEIGHT
59.3 Pounds

INTERPRETED BY
Eric Lindquist, DMV
DABVP, Cert. IVUSS

IMAGING PERFORMED BY
Shari Reffi, CVT

HOSPITAL NAME
Mount Olive VH

REFERRING VET
Dr. Jones

INVOICE
46501

DATE
4/7/23

however, this procedure is only performed at specific tertiary referral locations. Placement of palliative stents into the caudal vena cava (CVC) can be considered as well if compression by an unresectable tumor causes excessive ascitic fluid accumulation. Serum alpha-fetoprotein (AFP) has been shown to reemerge in dogs with malignant hepatobiliary adenocarcinoma. Ultrasound is important to localize the mass in relation to the portal hilus and gallbladder. The portal vein, CVC, aorta, gallbladder, and bile duct should all be identified with respect to the location of the mass to determine resectability. Ultrasound also allows for an examination of possible metastatic sites in the abdomen and, to some degree, in the thorax.

Treatment: Hepatic adenoma, hepatoma, and adenocarcinoma are usually amenable to surgical resection via hepatic lobectomy should the pathology be isolated to single-lobe progression. Multi-lobar presentation may be amenable to lobectomy and debulking; this will be determined further during surgical consultation. These tumors tend to displace unaffected parenchyma, allowing for relatively straightforward surgical resection. Up to 80% of the liver can be removed without long-term functional deficits. Blood transfusions may be necessary during surgery. The development and implementation of the LDS™ stapler has helped to streamline the procedure. Most carcinomas have metastasized by the time of diagnosis yet tend to be slow-growing; thus, it may be possible for a certain quality of life to be attained via surgical resection. Hepatic hemangiosarcoma has usually metastasized at the time of diagnosis and carries a much poorer prognosis. Surgical resection and chemotherapy are recommended, but considered by many to be an “aggressive” approach.

Preliminary trials have shown that gemcitabine is well tolerated and yields good responses in cases of hepatic as well as pancreatic, colonic, and gastric carcinomas. Myelosuppression, however, remains the key issue. Doxorubicin, cyclophosphamide, and fluorouracil combinations have also proven fruitful.

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been demonstrated to have an anti-neoplastic effect due to their inhibition of COX-2 in certain tumor cells. The end product of the cyclooxygenase cascade is prostaglandin E2, which, when expressed in tumor cell lines—and not expressed in normal cells of that particular cell line—results in inhibited apoptosis, immunosuppression, and increased angiogenesis, proliferation, and invasiveness. Inappropriate increases in COX-2 expression have been documented in certain neoplasias, including squamous cell carcinoma, mammary carcinomas, prostatic carcinoma, malignant melanoma, and transitional cell carcinoma.

Metronomic chemotherapy is currently being investigated and compared to traditional chemotherapy protocols; it is thought to be at least as effective as the latter with substantially less toxic side effects. Metronomic chemotherapy is the practice of uninterrupted administration of low-dose cytotoxic drugs at regular and frequent intervals, as opposed to high-dose, shorter-term protocols characteristic of traditional chemotherapeutic practices. The lower dose allows for long-term administration without toxic side effects, and has been postulated as providing longer remission intervals. Moreover, it has the benefit of minimizing the intervals between drug regimens—the period during which tumor cells may repopulate the area—as well as the chance of developing multi-drug resistant genes. Metronomic chemotherapy has been used successfully in human patients who have undergone previous chemotherapy administration. It is thought to destroy endothelial cells, thereby retarding angiogenesis and targeting regulatory T cells. To date, there have






SonoPath.com
1-800-838-4268 info@sonopath.com

PATIENT
Finnegan Koroski

SPECIES
Canine

BREED
Lab X

SEX
Neutered Male

AGE
2 Years

WEIGHT
59.3 Pounds

INTERPRETED BY
Eric Lindquist, DMV
DABVP, Cert. IVUSS

IMAGING PERFORMED BY
Shari Reffi, CVT

HOSPITAL NAME
Mount Olive VH

REFERRING VET
Dr. Jones

INVOICE
46501

DATE
4/7/23

only been a few small clinical trials in veterinary patients, and these have focused on animals that have hemangiosarcoma and soft tissue sarcomas.

Conclusion: With respect to hepatic neoplasia, many surgical and chemotherapeutic options exist; however, it is best to consult with a local board certified oncologist who can help determine the best course of action.

References:

Biller BJ. Teaching T cells to target tumors: towards the design of more effective cancer vaccines. Proceedings from the American College of Veterinary Internal Medicine Forum, Denver, CO, June 15-18, 2011.

Biller BJ, Guth A, Burton JH, Dow SW. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. *J Vet Intern Med* 2010;24(5):1118-23.

Elmslie RE, Glawe P, Dow SW. Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. *J Vet Intern Med* 2008;22(6):1373-79.

Lana S, U'Ren L, Plaza S, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. *J Vet Intern Med* 2007;21(4):764-69.

Milner RJ. Do NSAIDs make a difference in cancer? Proceedings from the American College of Veterinary Internal Medicine Forum, Denver, CO, June 15-18, 2011.